Prevalence of anti-Ro52 autoantibodies among patients with juvenile myositis
| Clinical subgroup | Anti-Ro52 autoantibody positive % (n/N) |
| Juvenile myositis (N=371) | 14% (n=53) *** |
| Juvenile dermatomyositis (N=302) | 14% (n=42) *** |
| Juvenile polymyositis (N=25) | 12% (n=3) * |
| Juvenile connective tissue-disease myositis (N=44): | 18% (n=8) *** |
| Juvenile lupus erythematosus (N=13) | 23% (n=3) ** |
| Juvenile systemic sclerosis (N=11) | 0% (n=0) |
| Juvenile idiopathic arthritis (N=7) | 29% (n=2) * |
| Other autoimmune diseases† (N=13) | 23% (n=3) ** |
| Myositis-specific autoantibody subgroup | |
| Anti-p155/140 (TIF-1) (N=119) | 11% (n=13) |
| Anti-NXP2 (N=77) | 14% (n=11) |
| Anti-MDA5 (N=32) | 31% (n=10) * |
| Antiaminoacyl tRNA synthetase (N=14) | 64% (n=9) *** |
| Anti-SRP (N=7) | 0% (n=0) |
| Anti-Mi2 (N=13) | 15% (n=2) |
| Anti-HMGCR (N=4) | 50% (n=2) |
| MSA negative (N=96) | 5% (n=5) ** |
| Juvenile healthy controls (N=90) | 1% (n=1) |
x² or Fisher’s exact tests were used to compare the percentage of positive patients compared with the percentage of negative patients within each myositis clinical and autoantibody subgroup.
*p<0.05, **p<0.01, ***p<0.001.
†autoimmune hepatitis, eosinophilic fasciitis, fasciitis, juvenile diabetes mellitus, lichen sclerosis, linear morphea, psoriasis, Sjögren’s syndrome, ulcerative colitis.
HMGCR, 3-Hydroxy-3-Methylglutaryl-CoA Reductase;MDA5, melanoma differentiation associated protein-5;MSA, myositis-specific autoantibody; NXP2, nuclear matrix protein-2;SRP, signal recognition particle;tRNA, transfer RNA;TIF-1, transcription intermediary factor 1.